Teede HJ, Tay CT, Laven JJE, et al
What discontinuation rates does the article report for dual therapy
Sustainable weight loss is about making small changes to your diet and lifestyle habits that fit into your life, not extreme overhauls
placebo over 52 weeks Efficacy observed both as monotherapy or combined with antifibrotics Well-tolerated, reduced death risk, though did not show statistically significant survival benefit Why it matters: Anti-inflammatory mechanism differentiates JASCAYD from existing antifibrotics (nintedanib, pirfenidone) Reinforces Boehringers leadership in respiratory innovation and re-energizes IPF R&D after years of limited breakthroughs Follow our page for more such updates: News Source: #FDAApproval #IPF #PulmonaryFibrosis #Respiratory #RespiratoryMedicine #DrugDevelopment #BoehringerIngelheim #Ofev #Esbriet #PharmaInnovation To view or add a comment, sign in This milestone marks a major advance for patients with progressive fibrotic lung disease, expanding treatment options beyond current antifibrotics
Because histamine triggers an inflammatory response in your body, the symptoms are almost the same
